CURRICULUM VITAE

PERSONAL INFORMATION:

Name and last name	Felice Cinque
Gender	Male
Date of birth	20/01/1994
E-mail	felice.cinque@unimi.it
PEC	cinque.felice@omceoromapec.it

EDUCATION AND QUALIFICATIONS:

October 2023 – October 2026 (ongoing)

PhD candidate in "Clinical research", Univeristy of Milan, Italy;

SC Medicina-Indirizzo Metabolico, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico di Milano, Milan, Italy. Chief physician and supervisor: Professor Anna Ludovica Fracanzani

November 2019 – November 2024

Specialization in Internal Medicine, University of Milan, Italy **with 70/70 cum laude.** Thesis Title: "Metabolic Dysfunction-Associated Steatotic Liver Disease in People with HIV: An International Cohort Analysis and Comparative Study with Men Using Pre-Exposure Prophylaxis for HIV Prevention". Supervisors: Professor Antonio Luca Brucato, Professor Rosa Lombardi

March 2019 – July 2019

Training as family medicine doctor, ASL RM-1, Rome, Italy.

14 March 2019

Italian medical license and registration to Ordine Provinciale dei Medici Chirurghi e degli Odontoiatri di Roma, Rome, Italy (registration number: 64570).

October 2012 - July 2018

Degree in Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy, **with 110/110 cum laude**, thesis title: “l'ipertensione arteriosa in una popolazione fragile: l'esperienza 2007-2017 di un poliambulatorio”. Supervisors: Professor Gianfranco Damiani and Doctor Salvatore Geraci.

July 2012

High school Diploma, Liceo Classico Dante Alighieri, Rome, Italy with 100/100.

PROFESSIONAL EXPERIENCES

Consultant Physician in Internal Medicine (January 2025 – ongoing), Metabolic Medicine Unit (SC Medicina – Indirizzo Metabolico), Fondazione IRCCS Ca’ Granda – Ospedale Maggiore Policlinico di Milano, Milan, Italy.
Chief Physician: Prof. Anna Ludovica Fracanzani

Resident Physician (Specialization in Internal Medicine, November 2019 – November 2024). Attendance of:

- Internal Medicine ward and Hepatologic Clinic, SC Medicina-Indirizzo Metabolico, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico di Milano, chief physician Prof.ssa Anna Ludovica Fracanzani (*November 2019 - December 2021; January 2024 – November 2024*).
- Abdominal ultrasound service, Unit of Hepatology and Gastroenterology at San Paolo Hospital of Milan, chief physician Professor Pier Maria Battezzati. (*January 2022 - March 2022*).

- Unit of Cardiological and Intensive Coronary Care and Echocardiography Ultrasound service, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico di Milano. Chief physician: Professor Stefano Carugo. (*April 2022 - June 2022* and *October 2022 - December 2022*)
- Emergency Department, Ospedale Sacco, Milano. Chief physician: Dott. Annamaria Brambilla; (*July 2022 - September 2022*)
- Chronic Viral Illnesses and hepatology outpatient clinic, McGill University Health Center, Montreal, Canada. Supervisor: Professor Giada Sebastiani; (*January 2023 – December 2023*)

EXPERIENCE ABROAD

January 2023 – December 2023

One-year research fellowship and clinical observership at Division of Gastroenterology and Hepatology and Division of Infectious Diseases, McGill University Health Centre, Montreal, Quebec, Canada. Supervisor: Professor Giada Sebastiani.

- Research program focused on liver disease in people with HIV and people with type 2 diabetes, with emphasis on metabolic liver disease.
- Attendance of McGill University academic courses (winter: EXMD 630 - Developing Digital Health Innovations for Impact; fall: EXMD 600 Principles of Clinical Research).
- Involvement in International Research Groups (Steatohepatitis in HIV Emerging Research [SHIVER] Network).
- Attendance of outpatient clinics of Hepatology and Infectious Diseases.
- Attendance of the On-call service of Hepatology and Liver Transplantation.

September 2017 – December 2017

Erasmus Program, Faculty of Medicine and Surgery, Cardiff University, Cardiff, UK.

August 2015

Clinical observership at Infectious Diseases ward, University of Edinburgh, Edimburgh, UK.

September 2014

Attendance of International Intensive Infectious Diseases Course “i3DC" - faculty of Medicine and Surgery A. Gemelli (IT), Université Paris Descartes (FR), l’University of Edinburgh (UK) and l'Universiteit
Antwerpen (BE).

August 2014 – September 2014

Attendance of Neurophysiology laboratory, UCLA - University of California Los Angeles - Los Angeles, USA. Supervisor: Professor Marco Iacoboni.

June 2011 – September 2011

High school exchange program, Wanaka, New Zealand.

RESEARCH ACTIVITY:

Clinical research activity in the following fields: 1) metabolic liver disease and steatosis in people living with HIV 2) diabetes and cardiovascular alterations 3) nutrition and lifestyle approaches to metabolic liver disease 4) role of genetic predisposition in liver disease 5) patient-centered care and social determinants of health

Co-investigator in several multicentric studies: REPOSI (Register of Multimorbidity and Polipharmacy), COVID-19 Network Working Group, PNEUMO study.

Sub-investigator in randomized pharmacological trials aimed at evaluating new drugs for the treatment of non-alcoholic steatohepatitis (ELIVATE, ESSENCE, GENFIT, INTERCEPT, AURORA).

PUBLICATIONS:

Author of 33 peer-reviewed papers, 8 as first author; Author of 62 conference abstracts.

H-index **(Scopus) 6**

ADVANCED COURSES (CORSI DI PERFEZIONAMENTO):

Scuola di Obesità della Società Italiana di Obesità (SIO), (January 2024).

Scuola Metodologia e Formazione in Ricerca clinica 2024, Società italiana di Medicina Interna, (May 2024)

Advanced course (corso di perfezionamento universitario) "Ricerca Clinica: Revisioni sistematiche e linee guida di studi di accuratezza diagnostica", University of Milan, Milan, Italy *(November 2022 – December 2022).*

Course "EXMD 630 - Developing Digital Health Innovations for Impact", McGill University, Montreal, Canada *(January 2023 – April 2023).*

Course "clinical ultrasound" with achievement of the national diploma in clinical ultrasound, SIUMB (Società Italiana di Ultrasonologia in Medicina e Biologia) (*November 2021-May 2022*).

PRIZES AND AWARDS:

Grants awarded:

Co-applicant of the Canadian Institutes of Health Research (CIHR) patient-oriented grant entitled *"ELITE-2D: Enhancing Liver Health for People with Type 2 Diabetes through Patient-Centered Strategies.* Duration 2025-2026. Funding source: CIHR, $210,000

Co-applicant of the Canadian Institutes of Health Research (CIHR) dissemination grant entitled "4th International Workshop of the Canadian NASH Network (CanNASH): "Towards a Canadian NASH Guidance". Duration: 2023/10 – 2024/9. Funding source: CIHR, $10,000

Co-applicant of the awarded "5th International Workshop of the Canadian NASH Network (CanNASH): A Canadian multistakeholder approach to the holistic management of MASLD". Duration: 2024/10 – 2025/9 Funding source: CIHR, $10,000

Prizes:

Best Research Abstract Study at European Congress of Internal Medicine (ECIM) 2022 for the abstract "Interaction between deterioration of lifestyle and genetic predisposition in NAFLD patients during COVID-19 lockdown".

Travel award at EASL (European association for the study of the liver) NAFLD Summit 2023 for the abstract "The effect of metabolic dysfunction-associated fatty liver disease on liver fibrosis progression and regression in virus-related liver disease: a multicenter longitudinal study"

Travel award at AASLD (American Association for the Study of Liver Diseases) The Liver Meeting 2023 for the abstract

"The effect of metabolic dysfunction-associated fatty liver disease on liver fibrosis progression and regression in virus-related liver disease: a multicenter longitudinal study" by the Research Network on CardioMetabolic health Diabetes and Obesity (CMDO) association.

Selected abstract at the SPRING meeting 2024 for the abstract "Metabolic dysfunction-associated steatotic liver disease in people with HIV is associated with lower BMI and more liver fibrosis compared to the uninfected population"

Poster of distinction at AASLD The Liver Meeting 2024 for the abstract "Balancing the Booze: How Light to Moderate Drinking Affects Liver and Cardiovascular outcomes in Steatotic Liver Disease

Travel award at AASLD (American Association for the Study of Liver Diseases) The Liver Meeting 2025 for the abstract "High burden of liver fibrosis in 4,809 people with HIV monoinfection undergoing screening for steatotic liver disease" by the Research Network on CardioMetabolic health Diabetes and Obesity (CMDO) association.

CONGRESS PARTICIPATION:

Oral Communication:

- **AISF** (Associazione Italiana per lo Studio delle malattie del Fegato): High burden of MASLD and metald in people with HIV: Acall for liver fibrosis screening prioritization.
- **CAHR (Canadian Association for HIV Research) 2023:** Hepatic steatosis in people with HIV is associated with lower BMI and more liver fibrosis compared to metabolic dysfunction-associated fatty liver disease.

- **The McGill Division of Gastroenterology & Hepatology Annual Carl. A. Goresky Research Day 2023**: Hepatic steatosis in people with HIV is associated with lower BMI and more liver fibrosis compared to metabolic dysfunction-associated fatty liver disease.
- **McGill Family Medicine Research Symposium 2023**: Hepatic steatosis in people with HIV is associated with lower BMI and more liver fibrosis compared to metabolic dysfunction-associated fatty liver disease.
- **ECIM (European Congress of Internal Medicine) 2022**: Interaction between deterioration of lifestyle and genetic predisposition in NAFLD patients during COVID-19 lockdown.

Poster presentation:

First author of abstracts and co-author of conference abstracts abstracts selected for presentation in Italian, Canadian and International congresses of Internal Medicine (SIMI, ECIM), Hepatology (AISF, EASL, AASLD, CLM), infectious diseases (CAHR, AIDS society), gastroenterology (UEG, ESNM).

Moderator:

Moderator of the Session 3 “Public health and policy” at the 4th International Workshop of the Canadian NASH Network (CanNASH): “Towards a Canadian NASH Guidance”.

CERTIFICATES:

September 2023: Fibroscan (Echosens, Paris) official training certificate

*February 2023***:** Certificate of Good Clinical Practice – Canada

February 2023: Certificate of Health Canada Division 5 - Drugs For Clinical Trials Involving Human Subjects

February 2023: Certificate of Human Research SOP Training IV – McGill University Health Centre

*October 2020***:** Certificate of ICH Good Clinical Practice E6 (R2)

SOCIAL ACTIVITIES:

May 2017 - March 2019: Volunteer at "Poliambulatorio Caritas di Roma", Rome (Italy). Poliambulatorio Caritas di Roma is a health service that provides free medical assistance to underprivileged patients, especially irregular migrants.

LANGUAGE:

Native language: Italian

English

Reading: C2.

Listening: C2

Writing: C1.

Speaking: C1.

TECHNICAL SKILLS:

Ability to use statistical software STATA (STATA Corp. LP, College Station, TX)

OTHER INFORMATIONS:

Member of Società Italiana di Medicina Interna (SIMI).
Member of Associazione Italiana per lo Studio del Fegato (AISF).

Member of European association for the study of the liver (EASL).

Member of American Association for the Study of Liver Diseases (AASLD).

Member of Canadian association for the study of the liver (CASL)

Member of the Research Network on CardioMetabolic health Diabetes and Obesity (CMDO).

List of Journal publications:

Original: 19

Review: 9

Editorial: 5

1. **Cinque F**, Fracanzani AL, Lombardi R: Metabolic dysfunction associated steatotic liver disease (MASLD) Treatment: Does Lifestyle Still Matter? Dig Liver Dis. 2025
2. **Cinque F**, Sebastiani G. Lifestyle first: tackling MASLD in people living with HIV. Lancet HIV. 2025 May 7:S2352-3018(25)00044-X. doi: 10.1016/S2352-3018(25)00044-X. Epub ahead of print. PMID: 40347963.
3. **Cinque F**, Nilo D, Gezzi A, De Gregorio F, Clerici B; Scuola di metodologia della ricerca, SIMI. Minimally invasive trans-sulcal parafascicular surgery for the early evacuation of spontaneous intracerebral hemorrhage: the ENRICH trial. Intern Emerg Med. 2025 Mar 3. doi: 10.1007/s11739-025-03907-5. Epub ahead of print. PMID: 40029567.
4. **Cinque F**, Long C, Dinh DA, Gore G, Swain M, Ramji A, Patel K, Betel M, Bajaj HS, Dasgupta K, Poder TG, Saeed S, Sebastiani G. Discrete Choice Experiments and Conjoint Analyses in Health Screening Programs for Type 2 Diabetes and Liver Disease: A Scoping Review. Can Liver J. 2025 Feb 25;8(1):63-78. doi: 10.3138/canlivj-2024-0050. PMID: 40678664; PMCID: PMC12269252.
5. Long C*, **Cinque F***, Kablawi D, Kim DHD, Tadjo TF, Elgretli W, Ballesteros LR, Lupu A, Nudo M, Lebouché B, Kronfli N, Cox J, Costiniuk CT, De Pokomandy A, Routy JP, Klein MB, Lamonde F, Agnihotram RV, Saeed S, Sebastiani G. Material deprivation is associated with liver stiffness and liver-related outcomes in people with HIV. Liver Int. 2024 Jul 16. doi: 10.1111/liv.16022. Epub ahead of print. PMID: 39011563.

   * Clara Long and Felice Cinque have contributed equally to this work

6. **Cinque F**, Saeed S, Kablawi D, Ramos Ballesteros L, Elgretli W, Moodie EEM, Price C, Monteith K, Cooper C, Walmsley SL, Pick N, Murray MCM, Cox J, Kronfli N, Costiniuk CT, de Pokomandy A, Routy JP, Lebouché B, Klein MB, Sebastiani G. Role of fatty liver in the epidemic of advanced chronic liver disease among people with HIV: protocol for the Canadian LIVEHIV multicentre prospective cohort BMJ Open. 22;13(8). Published 2023 Aug 22 doi:10.1136/bmjopen-2023-076547.
7. **Cinque F**, Cespiati A, Lombardi R, Guaraldi G, Sebastiani G. Nutritional and Lifestyle Therapy for NAFLD in People with HIV. *Nutrients*. 2023;15(8):1990. Published 2023 Apr 20. doi:10.3390/nu15081990.
8. **Cinque F**, Cespiati A, Lombardi R, et al. Interaction between Lifestyle Changes and PNPLA3 Genotype in NAFLD Patients during the COVID-19 Lockdown. Nutrients. 2022;14(3):556. Published 2022 Jan 27. doi:10.3390/nu14030556.
9. Nguyen T; Jackson W.E.; Roth N.C; **Cinque F**; Sarkar M; Samala N; Lee R.S; Strauss A.T; Wisocky J; Patel K; Sebastiani G; Streed C.G; Lake J.E; Lee T.H; Chronic Liver Diseases and Hepatology Care in Transgender and Gender Diverse Populations. Lancet Gastro Hep. Sept 2025
10. Righetti R, **Cinque F**, Lebouché B, Ramos Ballesteros L, Routy J-P, Klein MB, Szabo J, Cox J, Falutz J, Haraoui L-P; Distinct Gut Microbiota Signatures Are Associated with Severity of Metabolic Dysfunction-Associated Steatotic Liver Disease in People with HIV. International Journal of Molecular Sciences. 2025; 26(17):8165. https://doi.org/10.3390/ijms26178165
11. Lido P, Cantiero S, Galluccio A, Noce A, Di Lullo L, Bei R, Iellamo F, Mannucci PM, Nobili A, Tettamanti M; **REPOSI investigators**. Prescription of ACE-Is/ARBs in patients with cardio-renal disease: a multicenter retrospective cohort study from the REPOSI registry. Intern Emerg Med. 2025 Jul 15. doi: 10.1007/s11739-025-04026-x. Epub ahead of print. PMID: 40665006.
12. Longo M, Paolini E, Meroni M, **Cinque F**, Bertelli C, Pisano G, Maggioni M, Fracanzani AL, Lombardi R, Dongiovanni P. Next Generation Sequencing Allows Identification of a Novel Mutation in the TfR2 Gene and Outperforms the Conventional Diagnostic Techniques. EJHaem. 2025 Jun 26;6(4):e70073. doi: 10.1002/jha2.70073. PMID: 40574988; PMCID: PMC12198688.
13. Lombardi R, Forlano R, Maffi G, Cespiati A, **Cinque F**, Bignamini D, Dongiovanni P, Francione P, Sigon G, Huang J, Manousou P, Peyvandi F, Tripodi A, Fracanzani AL. Procoagulant imbalance is associated with hepatic and vascular complications in patients with MASLD and diabetes. Key role of factor VIII. Dig Liver Dis. 2025 Aug;57(8):1662-1668. doi: 10.1016/j.dld.2025.05.011. Epub 2025 Jun 19. PMID: 40541512.

14. Shengir M, Elgretli W, **Cinque F**, Ramanakumar AV, Lombardi R, Cespiati A, Fracanzani AL, Ballesteros L, Deschenes M, Wong P, Chen T, Sebastiani G. Metabolic Factors Drive Early Increase in Hepatic Steatosis Despite Improvement in Non-Invasive Fibrosis Markers after Hepatitis C Eradication with Direct-Acting Antivirals. Clin Res Hepatol Gastroenterol. 2025 Jun 16:102639. doi: 10.1016/j.clinre.2025.102639. Epub ahead of print. PMID: 40532848.
15. Lee TH, Wegermann K, Sutha K, Cholankeril G, Chu CY, Nguyen Galvan NT, Rana A, Goss JA, Lambing T, **Cinque F**, Sebastiani G, Patel K, Naggie S, Wolfe CR. Beyond the HOPE Act: Roadmap to Expanding Kidney and Liver Transplants for People with Human Immunodeficiency Virus Utilizing Grafts from Donors with Human Immunodeficiency Virus. Am J Transplant. 2025 May 12:S1600-6135(25)00267-9. doi: 10.1016/j.ajt.2025.05.013. Epub ahead of print. PMID: 40368062.
16. Burnside J, **Cinque F**, Sebastiani G, Ramji A, Patel K, Swain M, Saeed S. Sex differences in the prevalence and cardiometabolic risk profiles of steatotic liver disease: A Canadian Longitudinal Study on Aging analysis. Can J Public Health. 2025 May 5. doi: 10.17269/s41997-025-01025-5. Epub ahead of print. PMID: 40323353.
17. Elgretli W, Shengir M, Sasson S, Ramanakumar AV, **Cinque F**, Ballestreros LER, Deschenes M, Wong P, Chen T, Kronfli N, Saeed S, Keeshan A, Tandon S, Cooper C, Sebastiani G. Association of MASLD Phenotypes With Liver Fibrosis in Hepatitis C: The Role of Cardiometabolic Risk Factors. J Viral Hepat. 2025 Feb;32(2):e70004. doi: 10.1111/jvh.70004. PMID: 39868661; PMCID: PMC11771651.
18. Riccardo R, **Cinque F,** Patel K, Sebastiani G. The role of noninvasive biomarkers for monitoring cell injury in advanced liver fibrosis. *Expert Rev Gastroenterol Hepatol*. 2025 Jan 9:1-16. doi: 10.1080/17474124.2025.2450717. Epub ahead of print. PMID: 39772945.
19. Kablawi D, Milic J, Thomas T, Fotsing Tadjo T, **Cinque F**, Elgretli W, Gioè C, Lebouché B, Tsochatzis E, Finkel J, Bhagani S, Cascio A, Guaraldi G, Mazzola G, Saeed S, Sebastiani G. Metabolic dysfunction-associated steatohepatitis exhibits sex differences in people with HIV. *HIV Med*. 2024 Aug 1. doi: 10.1111/hiv.13697. Epub ahead of print. PMID: 39091015.
20. Riccardo R, **Cinque F**, Volpe MT, Sebastiani G. Integrating behavioral interventions into a Holistic Approach to Metabolic Dysfunction-Associated Steatotic liver disease. *Expert Rev Gastroenterol Hepatol.* 2024 Jul 29. doi: 10.1080/17474124.2024.2385487. Epub ahead of print. PMID: 39075881.
21. Alfieri CM, Molinari P, **Cinque F**, Vettoretti S, Cespiati A, Bignamini D, Nardelli L, Fracanzani AL, Castellano G, Lombardi R. What Not to Overlook in the Management of Patients with Type

2 Diabetes Mellitus: The Nephrological and Hepatological Perspectives. *International Journal of Molecular Sciences. 2024; 25(14):7728. https://doi.org/10.3390/ijms25147728*

22. Sebastiani G**, Cinque F**, Cascio A, Rockstroh JK, Guaraldi G. Inclusive healthcare in light of the new MASLD guidelines: Should people living with HIV be screened for liver fibrosis? J Hepatol. 2024 Jun 24:S0168-8278(24)02332-8. doi: 10.1016/j.jhep.2024.06.026. Epub ahead of print. PMID: 38925269.

23. Raggi P, Milic J, Manicardi M, **Cinque F**, Swain M, Sebastiani G, Guaraldi G. Metabolic dysfunction-associated steatotic liver disease: An opportunity for collaboration between cardiology and hepatology, *Atherosclerosis. 2024 May; 392:117523. doi: 10.1016/j.atherosclerosis.2024.117523. Epub 2024 Mar 16. PMID: 38522165.*

24. Guaraldi G, Milic J, Renzetti S, Motta F, **Cinque F**, Bischoff J, Desilani A, Conti J, Medioli F, Del Monte M, Kablawi D, Elgretli W, Calza S, Mussini C, Rockstroh JK, Sebastiani G. The effect of weight gain and metabolic dysfunction-associated steatotic liver disease on liver fibrosis progression and regression in people with HIV. AIDS. 2024 Jul 15;38(9):1323-1332. doi: 10.1097/QAD.0000000000003903. Epub 2024 Apr 18. PMID: 38597416; PMCID: PMC11216384.

25. Franchi C, Rossio R, Mandelli S, Ardoino I, Nobili A, Peyvandi F, Mannucci PM; **REPOSI Investigators.** Statins, ACE/ARBs drug use, and risk of pneumonia in hospitalized older patients: a retrospective cohort study. Intern Emerg Med. 2024 Apr;19(3):689-696. doi: 10.1007/s11739-023-03528-w. Epub 2024 Feb 14. PMID: 38353881.

26. Lombardi R, Colavolpe L, Alletto F, Cespiati A, Fatta E, Bertelli C, **Cinque F**, Pisano G, Pulixi E, Francione P, Oberti G, Maffi G, Iuculano F, Dongiovanni P, Meroni M, Burdick L, Bignamini D, Maggioni M, Valenti L, Fargion S, Fracanzani AL. Comparison of the severity of metabolic, liver and cardiovascular damage in NAFLD patients attending the hepatology clinic over the last three decades. Dig Liver Dis. S1590-8658(23)00761-2. Published 2023 Jul 26. doi:10.1016/j.dld.2023.07.009.

27. Cespiati A, **Cinque F**, Meroni M, Lombardi R, Dongiovanni P, Fracanzani AL. An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians. *Biomedicines*. 2023;11(2):586. Published 2023 Feb 16. doi:10.3390/biomedicines11020586.

28. Sebastiani G, Milic J, Tsochatzis EA, Marzolini C, Betel M, Bhagani S, Morse CG, **Cinque F**, Maurice JB, Ingiliz P, Price J, Lemoine M, Rockstroh JK, Guaraldi G; on behalf of the Steatohepatitis in HIV Emerging Research (SHIVER) Network. Letter to the editor: People living with HIV and NAFLD: A population left behind in the global effort for liver fibrosis screening?

[published online ahead of print, 2023 May 19]. *Hepatology*. 2023;10.1097/HEP.0000000000000465. doi:10.1097/HEP.0000000000000465

29. Succurro E, Novella A, Nobili A, Giofrè F, Arturi F, Sciacqua A, Andreozzi F, Pietrangelo A, Sesti G; **REPOSI Investigators**. Prescription appropriateness of anti-diabetes drugs in elderly patients hospitalized in a clinical setting: evidence from the REPOSI Register [published online ahead of print, 2023 Mar 25]. *Intern Emerg Med*. 2023;10.1007/s11739-023-03254-3. doi:10.1007/s11739-023-03254-3
30. Crisafulli E, Sartori G, Vianello A, Busti F, Nobili A, Mannucci PM, Girelli D; **REPOSI Investigators**. Clinical features and outcomes of elderly hospitalised patients with chronic obstructive pulmonary disease, heart failure or both. *Intern Emerg Med*. 2023;18(2):523-534. doi:10.1007/s11739-023-03207-w
31. Filtz A, Carandina A, Fasiello A, Barbetta L, Lombardi R, **Cinque F**, Rizzi G, Ceriani E, Furlan L, Bellocchi C, Fracanzani AL, Hu C, Cogliati C, Canetta C, Peyvandi F, Montano N, Tobaldini E. Remdesivir-induced bradycardia in patients hospitalized with SARS-CoV2 infection: a possible vagally-mediated mechanism. *Intern Emerg Med*. 2023;18(2):359-366. doi:10.1007/s11739-022-03168-6

    Journal's Impact IF: 5.472
32. Cicco S, D Abbondanza M, Proietti M, Zaccone V, Pes C, Caradio F, Mattioli M, Piano S, Marra AM, Nobili A, Mannucci PM, Pietrangelo A, Sesti G, Buzzetti E, Salzano A, Cimellaro A; Giovani Internisti Società Italiana di Medicina Interna (GIS-SIMI) and of the **REPOSI Investigators**. Antihypertensive treatment changes and related clinical outcomes in older hospitalized patients. *Eur J Clin Invest*. 2023;53(4):e13931. doi:10.1111/eci.13931
33. Lombardi R, Cespiati A, Francione P, **Cinque F**, Fargion S, Fracanzani AL. MAFLD AND NAFLD: is there the need for redefining the risk of cardiovascular disease and mortality?. *Metabolism and Target Organ Damage*. 2022; 2(1): 12. http://dx.doi.org/10.20517/mtod.2021.13

I authorize the use of my personal data in compliance with Legislative Decree 196/2003.

Milan, 06/10/2025

Signature